$BVAXF The latest clinical update strengthens the scientific case for the DPX platform.
$BIOV.CSE now needs regulatory execution, financing clarity and a development partner to unlock that value.
$MRNA $BNTX $CVAC
$BVAXF $BIOV.CSE setup is binary but clear: promising human data on one side, financing and reporting risk on the other.
Resolution of the filings could become as important as the next clinical announcement.
$MRNA $CVAC
$BVAXF thesis is platform validation. If DPX can consistently generate durable, antigen-specific T-cell responses, the opportunity extends beyond a single cancer indication.
$MRNA $BNTX $CVAC
$BVAXF Cancer vaccines have historically struggled with weak or short-lived immune activation. The $BIOV $BVAXF thesis rests on whether DPX can generate persistent, therapeutically relevant T-cell responses. $BNTX $MRNA $CVAC
I'm following the footprints on $CVAC—the 10-day VWAP is finally turning into a launchpad. 🏗️⚡
Setup: Perfect 8h pivot bottom; RSI is waking up from the dead (31) meaning the spring is officially loaded.
Unusual Flow: 13F filings show Citadel and Susquehanna shifting heavily into calls (+136%) as the merger floor solidifies. 🏗️
Target: Clearing the $4.37 wall triggers the gap-fill to the $6.83 bull targets. 📈
Safety: Stop below the $4.07 structural floor. 🧱 The BioNTech moat is absorbing the competition. Don't fight the $101.88 exchange reference price. 🚢📉 #hovdid
$CVAC Volatility reflects uncertainty about how effectively strategy converts into measurable outcomes. Cash flow visibility will determine how patient investors remain. A series of confirmed wins might reduce the required risk premium. In short, this remains an execution‑driven story with meaningful but conditional upside.
$CVAC: One Last Momentum Play? 🎯
Action: Up +2.18% today as liquidity dries up ahead of the Jan buyout
Catalyst: Compulsory acquisition in Jan 2026 will clean up remaining 13.2% of float
Support: Rock solid at $3.80; Bulls holding the red trendline
PT: Fair value sitting near the $5.43 analyst median for those still holding RSI is screaming oversold—watch for a final liquidity grab before it’s gone. 🔋💎 #hovdid
$CVAC
The P/E ratio will show its potential for improvement through synergies as early as next year. Most importantly, there will be no more internal legal disputes and 1,000 new patents for $BNTX . CureVac's expertise should help BioNTech get closer to the approval of mRNA-based cancer therapies. They are just one step away. This is a major undertaking, and I am convinced it will be worth significantly more than $1.25 billion in the long run.
